VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026

The business combination of VERAXA Biotech and Voyager Acquisition Corp. was closed successfully and NASDAQ trading of $VRXA commences on June 11, 2026.